Annexon, Inc. · NASDAQ:ANNX
Annexon — 11th Congress of the European Academy of Neurology 2025
8 slides from Annexon's conference presentation, June 2025
Slide 1: A Bayesian ordinal transition model of Guillain-Barré syndrome disability progression with anti-C1q treatment
A Bayesian ordinal transition model of Guillain-Barré syndrome (GBS) disability progression with anti-C1q treatment Presenter: Glenn Morrison, MSc, PhD Ping Lin, MS1; Maximilian Rohde, MS2; Henk-André Kroon, MD, MBA1; Ewout Steyerberg, MSc, PhD3; Glenn Morrison, MSc, PhD1; Kenneth C. Gorson, MD4; Qu
Slide 2: GBS-02: Double-blind, Phase 3 study in adults with Guillain-Barré Syndrome
GBS-02: Double-blind, Phase 3 study in adults with Guillain-Barré Syndrome (NCT04701164) • GBS, a rare, rapidly progressive and life-threatening neuromuscular emergency is a prototypical classical complement-mediated disease1,2 Tanruprubart (ANX005) rapidly and completely inhibits C1q, preventing cl
Slide 3: GBS-DS: Used to assess functional status in patients with GBS
GBS-DS: Used to assess functional status in patients with GBS GBS-DS GRADES1 A healthy state Minor symptoms Able to walk 10 m Able to walk 10 m Bedridden or Requiring assisted Dead and capable or more without across an open chairbound ventilation of running assistance but space with help for at leas
Slide 4: Methods
Methods • Prespecified secondary endpoint: to analyze the proportion of participants that reached a healthy state (GBS-DS=0 [normal]) calculated using logistic regression • A Bayesian ordinal transition model with a first-order Markov transition structure was fit in a post hoc analysis to the longit
Slide 5: Results: Durable benefit with tanruprubart over placebo
Results: Durable benefit with tanruprubart over placebo At Week 26, participants who received tanruprubart 30 mg/kg had 4.1-fold greater odds of having fully recovered to GBS-DS=0 compared with participants who received placebo OR, 4.1 25 Tanruprubart 30 mg/kg (n=79) p=0.0092* Placebo (n=81) 21.5 20
Slide 6: Results: Conditional probability of health state achievement
Results: Conditional probability of health state achievement for tanruprubart 30 mg/kg vs placebo Participants receiving tanruprubart had a higher probability of good health status at each visit through 6 months, compared with placebo, and improvements occurred rapidly within the first 3 weeks Cumul
Slide 7: Results: Difference in mean visits recovered
Results: Difference in mean visits recovered with tanruprubart 30 mg/kg vs placebo (covariate adjustment) On average, participants receiving tanruprubart 30 mg/kg were more likely to have more study visits with GBS-DS=0 throughout the study versus those receiving placebo, with a high posterior proba
Slide 8: Conclusion
Conclusion Tanruprubart 30 mg/kg demonstrated rapid and sustained improvement through 6 months Bayesian ordinal transition models can increase power and present a longitudinal view of treatment effect, compared with traditional cross-sectional methods, providing more actionable evidence about effica
Annexon — 11th Congress of the European Academy of Neurology 2025 on 6ix